Barnes G, Sears L, Sullivan J. Safety and tolerability of GWP42006 (cannabidivarin) in subjects with drug resistant epilepsy and autism spectrum disorder. Poster presented at: 2019 International Society for Autism Research Meeting; May 1-4, 2019; Montreal, Québec, Canada. Poster 31296.
Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the Fourteenth EILAT Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia. 2018;59:1842-1866.
ClinicalTrials.gov. A study of GWP42006 in people with focal seizures - part B. https://clinicaltrials.gov/ct2/show/NCT02365610. Accessed May 4, 2020.
ClinicalTrials.gov. Safety and tolerability of cannabidivarin (CBDV) in children and young adults with autism spectrum disorder. https://clinicaltrials.gov/ct2/show/NCT03202303. Accessed May 4, 2020.
Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55:791-802.
Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011-2020.
Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270-278.
Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med. 2018;378:1888-1897.
Devinsky O, Verducci C, Thiele EA, et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131-137.
FDA briefing document. Peripheral and Central Nervous System Drugs Advisory Committee Meeting. April 19, 2018. NDA 210365 cannabidiol. US Food and Drug Administration website. https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-19-2018-meeting-peripheral-and-central-nervous-system-drugs-advisory-committee-meeting. Accessed May 1, 2020.
French JA, Koepp M, Naegelin Y, et al. Clinical studies and anti-inflammatory mechanisms of treatments. Epilepsia. 2017;58(Suppl 3):69-82.
Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017;32:35-40.
Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57:1617-1624.
McCoy B, Wang L, Zak M, et al. A prospective open‐label trial of a CBD / THC cannabis oil in Dravet syndrome. Ann Clin Transl Neurol. 2018;5:1077-1088.
Messenheimer JA, O'Brien T, Berkovic S, et al. Ongoing in developmental and epileptic encephalopathies, including half of patients with LGS and Dravet. Poster presented at: Annual Meeting of the American Academy of Neurology; April 20, 2018; Los Angeles, CA. Poster P4.468.
Morano A, Fanella M, Albini M, et al. Cannabinoids in the treatment of epilepsy: current status and future prospects. Neuropsychiatric Dis Treatment. 2020;16:381-396.
O'Brien T, Berkovic SF, French J, et al. Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults. Poster presented at: American Epilepsy Society meeting; December 1-5, 2017; Washington, DC. Poster 2.428.
O'Brien T, Berkovic WF, French J, et al. Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults. Poster presented at: American Epilepsy Society meeting; November 30-December 4, 2018. New Orleans, LA. Poster 2.253.
Rosenberg EC, Louik J, Conway E, et al. Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia. 2017;58:e96-e100.
Rosenberg EC, Tsien RW, Whalley BJ, et al. Cannabinoids and epilepsy. Neurotherapeutics. 2015;12:747-768.
Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;89:741-753.
Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46:86-95.
Sylantyev S, Jensen TP, Ross RA, et al. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A. 2013;110:5193-5198.
Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59:1540-1548.
Taylor L, Gidal B, Blakey G, et al. A phase I randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32:1053-1067.
Thiele E, Bebin EM, Bhathal H, et al. Cannabidiol (CBD) treatment in patients with seizures associated with tuberous sclerosis complex: a randomized, double-blind, placebo-controlled phase 3 trial (GWPCARE6). Presented at: American Epilepsy Society annual meeting; December 6-10, 2019; Baltimore, MD. Abstract 1.293.
Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085-1096.
VanLandingham K, Jones N, Gray R, et al. Cannabidivarin: preclinical and initial clinical data on seizures and future development. Presented at: EILAT XIV; May 13-16, 2018; Madrid Spain.
Vigli D, Cosentino L, Raggi C, et al. Chronic treatment with the phytocannabinoid cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome. Neuropharmacology. 2018;140:121-129.

CME / ABIM MOC / CE

A Quick Reference Guide to the Therapeutic Use of Cannabinoids in Epilepsy

Authors: Orrin Devinsky, MD
CME / ABIM MOC / CE Released: 6/8/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/8/2021

Target Audience and Goal Statement

This activity is intended for neurologists, pediatricians, primary care physicians, and pharmacists.

The goal of this activity is to increase clinicians’ knowledge of clinical data pertaining to FDA-approved and investigational antiseizure cannabinoid-based therapies.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Anti-seizure mechanisms of cannabinoid-based therapies
- Clinical data relating to the use of cannabinoids for the management of seizure conditions

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Orrin Devinsky, MD

Professor of Neurology, Neuroscience, Neurosurgery, & Psychiatry
NYU Grossman School of Medicine
Director
Comprehensive Epilepsy Center
NYU Langone Medical Center
New York, New York

Disclosures

Disclosure: Orrin Devinsky, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: California Cannabis Enterprises; GW Pharmaceuticals; Papa & Barkley; Receptor Life Sciences; Tilray
Received grants for clinical research from: GW Pharmaceuticals; Stoke Therapeutics; Zogenix
Owns stock, stock options, or bonds from: California Cannabis Enterprises; GW Pharmaceuticals; Papa & Barkley; Receptor Life Sciences; Tilray

Steering Committee

Elizabeth A. Thiele, MD, PhD

Professor of Neurology
Harvard Medical School
Director
Pediatric Epilepsy Program
Director
Carol and James Herscot Center for Tuberous Sclerosis Complex
Massachusetts General Hospital
Boston, Massachusetts

Disclosures

Disclosure: Elizabeth Thiele, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Aquestive; Biocodex; GW Pharma/Greenwich Biosciences Inc.; Thor Laboratories; West Therapeutics; Zogenix
Served as a speaker or a member of a speakers bureau for: GW Pharma/Greenwich Biosciences Inc.
Received grants for clinical research from: GW Pharma; Zogenix

Michelle H. Cameron, MD, PT, MCR

Associate Professor of Neurology
Oregon Health & Sciences University
Portland, Oregon

Disclosures

Disclosure: Michelle Hannah Cameron, MD, PT, MCR, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Adamas Pharmaceuticals; Greenwich Biosciences, Inc.

Tyler E. Gaston, MD

Assistant Professor of Neurology
University of Alabama
Birmingham, Alabama

Disclosures

Disclosure: Tyler E. Gaston, MD, has disclosed no relevant financial relationships.

Barry E. Gidal, PharmD

Professor of Pharmacy
Professor of Neurology
University of Wisconsin
Madison, Wisconsin

Disclosures

Disclosure: Barry E. Gidal, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Aquestive; Eisai; Greenwich Biosciences Inc.; Neurelis; Sunovion
Served as a speaker or a member of a speakers bureau for: Eisai; Greenwich Biosciences Inc.; Sunovion
Received grants for clinical research from: UCB

Patricia McGoldrick, NP, MPA, MSN

Co-Director of Pediatric Epilepsy and EMU
Boston Children's Health Physicians - Westchester and Connecticut
Maria Fareri Children's Hospital
Valhalla, New York

Disclosures

Disclosure: Patricia McGoldrick, NP, MPA, MSN, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eisai; Greenwich Biosciences Inc.; Lundbeck; Mallinkrodt; Neuropace; Sunovion; Supernus
Served as a speaker or a member of a speakers bureau for: Eisai; Greenwich Biosciences Inc.; Lundbeck; Mallinkrodt; Sunovion; Supernus
Received grants for clinical research from: Lundbeck

Anup Patel, MD

Associate Professor of Clinical Pediatrics and Neurology
The Ohio State University College of Medicine
Section Chief
Pediatric Neurology
Nationwide Children's
Columbus, Ohio

Disclosures

Disclosure: Anup Patel, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: GW Pharma; Stoke

Editors

Catherine Friederich Murray, MNLM

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Catherine Friederich Murray, MNLM, has disclosed no relevant financial relationships.

Zach Hartman, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Zach Hartman, PhD, has disclosed no relevant financial relationships.

CME, CE Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-20-294-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Neurology & Neurosurgery

CME / ABIM MOC / CE

A Quick Reference Guide to the Therapeutic Use of Cannabinoids in Epilepsy

Authors: Orrin Devinsky, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 6/8/2020

Valid for credit through: 6/8/2021

processing....

Educational Impact Challenge

The goal of this activity is to increase clinicians’ knowledge of clinical data pertaining to FDA-approved and investigational antiseizure cannabinoid-based therapies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Patient Handout

Clinician Handout

Page 1 of 4

CME / ABIM MOC / CE Information Download Slides

Activity Transcript

PDF Downloads

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Orrin Devinsky, MD

Steering Committee

Elizabeth A. Thiele, MD, PhD

Michelle H. Cameron, MD, PT, MCR

Tyler E. Gaston, MD

Barry E. Gidal, PharmD

Patricia McGoldrick, NP, MPA, MSN

Anup Patel, MD

Editors

Catherine Friederich Murray, MNLM

Zach Hartman, PhD

CME, CE Reviewer

Esther Nyarko, PharmD

CME / ABIM MOC / CE

A Quick Reference Guide to the Therapeutic Use of Cannabinoids in Epilepsy

Target Audience and Goal Statement

Disclosures

Faculty

Orrin Devinsky, MD

Steering Committee

Elizabeth A. Thiele, MD, PhD

Michelle H. Cameron, MD, PT, MCR

Tyler E. Gaston, MD

Barry E. Gidal, PharmD

Patricia McGoldrick, NP, MPA, MSN

Anup Patel, MD

Editors

Catherine Friederich Murray, MNLM

Zach Hartman, PhD

CME, CE Reviewer

Esther Nyarko, PharmD

Accreditation Statements

For Physicians

For Pharmacists

Instructions for Participation and Credit

A Quick Reference Guide to the Therapeutic Use of Cannabinoids in Epilepsy

Educational Impact Challenge

PDF Downloads